Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Background Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET expression as the disease progresses to more advanced stages and to a castration resistant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Monk, Paul, Liu, Glenn, Stadler, Walter M., Geyer, Susan, Huang, Ying, Wright, John, Villalona-Calero, Miguel, Wade, James, Szmulewitz, Russell, Gupta, Shilpa, Mortazavi, Amir, Dreicer, Robert, Pili, Roberto, Dawson, Nancy, George, Saby, Garcia, Jorge A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Phase II Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153554/
https://ncbi.nlm.nih.gov/pubmed/30083962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0630-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados